Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Mr. Stig  Ogata

Vice President of Corporate Communications

Ms. Tatjana  Dragovic

Senior Vice President and Head of Ethics & Compliance

Mr. Katsuyoshi  Sugita

Chief People Officer, Chief Ethics & Compliance Officer, EVice President of HR and Representative Director

Mr. Naoki  Okamura BSc

President, Chief Executive Officer & Director

Mr. Atsushi  Kitamura

Chief Financial Officer

Nobue  Yasuda

General Manager of Finance & Accounting Department

Ms. Catherine B. Levitt

General Counsel

Ms. Collette  Taylor

Senior Vice President of Human Resources

Mr. Nobuaki  Tanaka

President of Japan Commercial & Senior Corporate Executive

Mr. Yoshitsugu  Shitaka Ph.D.

Chief Scientific Officer & Senior Managing Executive Officer

Nume	Capitalizare de piață
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
PT Kalbe Farma Tbk.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
NGL Fine-Chem Limited	0M
Bristol-Myers Squibb Company	0M
Orion Oyj	0M
Chugai Pharmaceutical Co., Ltd.	0M
Novartis AG	0M

Astellas Pharma Inc.

Astellas Pharma Inc. Lista concurenților

Principalii concurenți